1Daar ES, Ha DD. Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4[J]. Am J Med,1991, 90(4A): 22S-26S.
2Mitchell D. Two new types of anti-HIV drugs show promise in preclinical studies [EB/OL]. http://www.aidsmeds.com. 2002-02-26.
3Shaunak S, Thornton M, John S, et al. Reduction of the viral road of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDS[J]. AIDS, 1998, 12(4):399-409.
4Flexner C. New drugs: attacking chemoking receptors [EB/OL]. http://www.Hopkins-aids. edu. 2002.
5Chan DC, Fass D, Berger JM, et al. Core structure of gp41 from the HIV envelope glycoprotein [J]. Cell, 1997, 89(2):263-273.
6Trimeris. T-1249, The promises of expanding HIV treatment options. [EB/OLJ http://www.trimeris.com 2002 .
7Menendez-Arias L. Targeting HIV:antiretroviral therapy and development of drug resistance [J]. Trends Pharmacol Sci,2002, 23(8):381-388.
8De Clercq E. New developments in anti-HIV chemotherapy[J]. Biochim Biophys Acta, 2002, 1587(2-3): 258-275.
9Fung HB, Stone EA, Piacenti FJ. Tenofovir Disoproxil Fumarate: A Nucleotide Reverse Transcriptase Inhibitor for the Treatment of HIV Infection[J]. Clin Ther, 2002, 24(10):1515-1548.
10Wamberg M, Pedersen EB, El-Brollosy NR, et al. Synthesis of 6-arylvinyl analogues of the HIV drugs SJ-3366 and Emivirine[J]. Bioorg Med Chem, 2004, 12(5): 1141-1149.
